Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02514577 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of IDP-122 in the Treatment of Participants With Plaque Psoriasis
A Phase 3 study of Plaque Psoriasis, sponsored by Bausch Health Americas.
- Completed
- Registry status
- Phase 3
- Development phase
- 217
- Enrollment target
- 15
- Study locations
NCT02514577 is a Phase 3 study of Plaque Psoriasis that has completed, run by Bausch Health Americas. The registered enrollment target is 217 participants, below the 411-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (47% lower). The trial reports 15 study locations across 11 states.
The verdict
NCT02514577, a Phase 3 study of Plaque Psoriasis, has completed, sponsored by Bausch Health Americas.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 217 participants
- Enrollment target
- 15
- Study locations
Study Summary
This study is to evaluate the safety and efficacy of a topical lotion when applied once daily to adult participants with moderate to severe plaque psoriasis (defined as an Investigator's Global Assessment \[IGA\] score of 3 or 4).
Conditions Studied
Interventions
- DRUG IDP-122 Lotion
- DRUG IDP-122 Vehicle Lotion
Study Locations (15)
California
- Valeant Site 1 - Encinitas
- Valeant Site 10 - Encino
- Valeant Site 12 - Santa Rosa
Michigan
- Valeant Site 4 - Ann Arbor
- Valeant Site 8 - Clarkston
Texas
- Valeant Site 3 - Austin
- Valeant Site 2 - San Antonio
Arkansas
- Valeant Site 11 - Hot Springs
Georgia
- Valeant Site 13 - Atlanta
Idaho
- Valeant Site 7 - Boise
Maryland
- Valeant Site 6 - Rockville
Nevada
- Valeant Site 15 - Las Vegas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 217 participants |
| Start Date | 2015-11-07 |
| Est. Completion | 2017-05-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02514577
The ClinicalTrials.gov registry entry for NCT02514577 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 217 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 411-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (47% lower). The listed sponsor is Bausch Health Americas, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Plaque Psoriasis appearing as the primary indexed condition, and to 2 interventions - of which IDP-122 Lotion is the first listed.
NCT02514577 reports 15 study locations spanning 11 distinct geographic areas - top geographies include California, Michigan, Texas.
Frequently Asked Questions
What is clinical trial NCT02514577 about?
NCT02514577 is a clinical study titled "Safety and Efficacy of IDP-122 in the Treatment of Participants With Plaque Psoriasis". This study is to evaluate the safety and efficacy of a topical lotion when applied once daily to adult participants with moderate to severe plaque psoriasis (defined as an Investigator's Global Assessment \[IGA\] score of 3 or 4).
What is the current status of trial NCT02514577?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 217 participants. The study started on 2015-11-07. Estimated completion is 2017-05-01.
What conditions does trial NCT02514577 study?
This clinical trial studies the following conditions: Plaque Psoriasis.
What interventions are being tested in trial NCT02514577?
The interventions under investigation include: IDP-122 Lotion (DRUG), IDP-122 Vehicle Lotion (DRUG).
Who is sponsoring clinical trial NCT02514577?
This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02514577 being conducted?
This trial has 15 study locations across Arkansas, California, Georgia, Idaho, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Plaque Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
RECRUITING · Phase 3
-
A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
RECRUITING · Phase 3
-
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
ACTIVE NOT RECRUITING · Phase 3
-
A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)
ACTIVE NOT RECRUITING · Phase 3
-
Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.